期刊
FRONTIERS IN NEUROLOGY
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2019.00291
关键词
biomarker; motor neuron disease (MND); ALS (Amyotrophic lateral sclerosis); neuroimaging; cerebrospinal fluid (CSF); electrophysiology; biofluid
资金
- Motor Neurone Disease Association (AMBROSIA Programme) [MND005348]
- British Society for Clinical Neurophysiology
- NIHR Sheffield Biomedical Research Centre: Translational Neuroscience for Chronic Neurological Disorders
- NIHR [NF-S1-0617-10077]
- NIHR Sheffield Clinical Research Facility
- MRC [MR/K000039/1, MR/S004920/1] Funding Source: UKRI
Motor neuron disease can be viewed as an umbrella term describing a heterogeneous group of conditions, all of which are relentlessly progressive and ultimately fatal. The average life expectancy is 2 years, but with a broad range of months to decades. Biomarker research deepens disease understanding through exploration of pathophysiological mechanisms which, in turn, highlights targets for novel therapies. It also allows differentiation of the disease population into sub-groups, which serves two general purposes: (a) provides clinicians with information to better guide their patients in terms of disease progression, and (b) guides clinical trial design so that an intervention may be shown to be effective if population variation is controlled for. Biomarkers also have the potential to provide monitoring during clinical trials to ensure target engagement. This review highlights biomarkers that have emerged from the fields of systemic measurements including biochemistry (blood, cerebrospinal fluid, and urine analysis); imaging and electrophysiology, and gives examples of how a combinatorial approach may yield the best results. We emphasize the importance of systematic sample collection and analysis, and the need to correlate biomarker findings with detailed phenotype and genotype data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据